Abstract 477P
Background
Lower grade gliomas (LGGs) represent 15% of all primary brain tumors, and have variable prognosis. The prognostic influence of the ENHO gene in LGGs remains elusive, necessitating further bioinformatic exploration to improve patient management and outcomes.
Methods
Differential gene expression based on High/low ENHO expression was extracted using the “DESeq2” R package. Immune infiltration, mutational burden, gene set variation analysis (GSVA) and drug resistance were analyzed through GSCALite and cBioPortal. Additional immune infiltration and survival analysis used TIMER2.0. Gene set enrichment analysis (GSEA) was conducted via TCGAbiolinks and enriched further using Enrichr.
Results
Multivariate overall survival (OS) analysis showed a protective effect for ENHO (HR = 0.58, p <0.001). GSVA for OS and progression-free survival (PFS) for co-expressed genes and upregulated genes also showcased favorable prognosis OS:(HR = 0.40, p<0.001) and (HR = 0.34, p<0.001), respectively; PFS: (HR = 0.53, p<0.001) and (HR = 0.44, p<0.001), respectively. Survival GSVA of downregulated genes revealed an association with worse OS (HR = 4.19, p < 0.001) and PFS (HR = 2.45, p< 0.001). GSVA for upregulated genes showed a negative correlation with DNA damage, EMT, and PI3KAKT pathways. GSVA for downregulated genes had a positive correlation with EMT, DNA damage, and PI3K/AKT pathways. GSVA for co-expressed genes revealed significant negative correlations with DNA damage and EMT pathways. Mutational burden analysis revealed that shallow deletion is the most common ENHO mutation among all LGG subtypes, regardless of stage. Immune infiltration analysis for ENHO, upregulated, and co-expressed genes showcased the infiltration of: Central memory B cells, CD8 T cells, Neutrophils, and CD4 T cells. Decreased infiltration of cancer associated fibroblasts was observed for high ENHO expression. GSEA of coexpressed genes revealed significant involvement in cell cycle processes and regulation.
Conclusions
ENHO's role in LGG is yet to be determined, but our results showcase a possible protective effect through its modulation of the immune system, cell cycle signalling, and EMT pathways. Primary studies are still needed to validate ENHO's role in LGG.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16